Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL — Stella

Home/Precursor B-Cell Acute Lymphoblastic Leukemia/Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

View on ClinicalTrials.gov

Recruiting

Back to Precursor B-Cell Acute Lymphoblastic Leukemia trials

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

Key details

Phase

Safety & dosing

Sponsor

First Affiliated Hospital of Zhejiang University

Enrollment target

~36 participants

Started

December 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.